Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based bismuth quadruple therapy vs PPI-based bismuth quadruple therapy for first-line Helicobacter pylori eradication in penicillin-allergic patients
ChiCTR2300075609Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Eradication rates of Helicobacter pylori. Started Sep 2023; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300075609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075609.